Bailey Health Solutions Review: A Documented GLP-1 Service, With Important Evidence Gaps

01Start with the preparation, not the GLP-1 label

The most important unresolved detail is the medication’s identity. Bailey’s offer repeatedly describes compounded GLP or GLP-1 medication with B-12. Although the page title mentions semaglutide, the offer’s body does not clearly establish the active ingredient actually dispensed. It also does not identify the pharmacy, its location or the preparation’s specific formulation. The documented route is injection, but the public material does not define the presentation or quantity supplied with each shipment.

That leaves a substantial gap between a treatment category and a verifiable product. Readers should request the proposed prescription’s exact ingredient, formulation, presentation and pharmacy before treating outside research as applicable. B-12 is part of Bailey’s advertised preparation; its inclusion does not itself demonstrate additional weight-loss benefit. The distinction explored in our guide to formulation and route evidence is particularly relevant when the public offer gives a category name rather than a complete medication description.

FDA states that compounded preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. That does not, by itself, prove clinical inequivalence or establish that Bailey’s service is unsafe. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Bailey’s documentation does not resolve how that recommendation would apply to a particular proposed prescription.

02What clinical research can—and cannot—say about Bailey

The clinic’s GLP-1 page includes broad promotional statements about health benefits, but the consulted documentation does not establish measured outcomes for Bailey’s program. It does not provide a program-specific clinical study showing results for the preparation offered here. This is an evidence limitation, not proof that patients cannot benefit. It means the clinic’s service description and commercial claims should not be read as an outcomes report.

STEP 1 studied subcutaneous semaglutide in adults with obesity or overweight plus a weight-related condition, without diabetes. SURMOUNT-1 studied subcutaneous tirzepatide in a similarly defined population excluding diabetes. Neither was a trial of Bailey Health Solutions or its compounded B-12 preparation. Their findings do not establish results for an unidentified formulation, a vitamin blend or an individual patient. Our explanation of why clinical trials are not company performance reports develops that distinction.

The practical evidence question is therefore narrower than whether GLP-1 medications have been researched. It is whether the proposed product and clinical circumstances match the evidence being cited, and where they do not. Bailey’s unspecified active ingredient prevents a confident product-level comparison from its public pages alone. A consultation should clarify the medication before discussing trial expectations, rather than using familiar drug names or headline weight-loss figures to fill that documentary gap.

03The first visit establishes a process, not automatic eligibility

Bailey says the first weight-loss visit can take place in its office or through telehealth. The discussion covers current physical health, weight-loss goals and previous efforts. Its separately listed free initial visit includes consultation, answers about compounded GLP preparations with B-12, examination of current health and review of recent blood tests. These are useful, concrete descriptions of an entry appointment, although the pages do not explain how the examination differs between remote and in-person visits.

The clinic lists possible candidates as people with 25 or more pounds to lose, polycystic ovary syndrome or type 2 diabetes. It also mentions people ready to change their diet and those who have struggled to maintain weight loss. These are the provider’s broad candidate descriptions, not an approval guarantee or a complete clinical screening protocol. The consulted documentation does not set out a full list of contraindications, exclusions or program-specific BMI requirements.

If blood work has not been completed in the past year, Bailey says it will perform a weight-loss panel. Medication ordering follows receipt and review of laboratory results, provided the person is considered a suitable candidate. The panel’s contents and price are not specified. NIDDK explains that medication selection also involves current conditions, other medicines, side effects, family history and costs; patients should bring that information rather than assume a marketing category settles eligibility.

04The price is visible; the complete billing rules are not

Bailey advertises a regular price of $389 per month for its compounded GLP-1 with B-12 program and $50 off the first month. The page also states “No contracts,” “No added fees,” “No membership fees” and “Month to month pricing.” These are meaningful commercial representations. The free initial visit is separately described and should not be confused with free medication or an entirely free first month of treatment.

The public material does not itemize laboratory work, injection supplies or transportation charges, despite the broad no-added-fees statement. It also does not explain whether price varies with formulation or quantity, or define the supply period per shipment. Readers should seek a written description of what the advertised monthly payment purchases. A monthly price does not by itself establish the amount dispensed, the exact billing date or an obligation to prepay several months.

The homepage advertises acceptance of many insurance plans and availability of payment plans, but does not expressly connect either to this GLP-1 offer. Insurance acceptance for other clinic services should not be read as confirmed coverage here. Likewise, month-to-month pricing and no contracts do not explain automatic renewal, cancellation steps, notice requirements or refunds. Those details remain unavailable in the consulted documentation; cancellation and reimbursement are separate questions that need separate answers.

05Who delivers care, and what follow-up actually means

Bailey presents itself as an integrative healthcare clinic combining medical and natural approaches. Its team page lists Jason Bailey, D.C., whom it says has practiced since 1998 and moved his practice from Miami to St. Augustine in 2015. It also lists Chastity Haltam, APRN; Rachel Lahav, PA, whose stated specialties include weight loss; and Zehra Cumber, D.O. These are the credentials published by the clinic, not independently verified licensing findings.

The team listing does not identify who evaluates or prescribes for each GLP-1 patient. The distinctions matter: a D.C. is a chiropractic credential, an APRN is an advanced practice registered nurse, a PA is a physician assistant and a D.O. is an osteopathic physician. Naming several professionals does not establish their individual responsibilities in this program. A prospective patient should ask who conducts the assessment, signs the prescription and handles questions between appointments.

Bailey promises close practitioner monitoring and individualized treatment decisions. It advertises weekly visits as available but not required, and says a health coach discusses a customized diet plan after the target dose is reached. These are documented service promises, not evidence of a fixed monitoring schedule or measured benefit. As our guide to clinical follow-up beyond renewals explains, useful follow-up concerns treatment response and tolerability, not merely continued payment.

06Injection instruction and shipping need separate verification

After laboratory review and a suitability decision, Bailey says it will order and ship the compounded medication with B-12 to the patient’s residence. Staff then demonstrate the injection in the office or through telehealth. Local patients may instead come to the office weekly for their injection. That is a useful distinction between learning home administration and choosing clinic-based administration; the documentation does not say that weekly office attendance is mandatory.

The clinic says medication can ship to most states, but the consulted pages do not name them or explain state-specific telehealth access. They also omit the carrier, preparation and dispatch timelines, arrival estimates, package tracking, refrigeration procedures and handling of lost or damaged shipments. A shipment promise is not a delivery timetable. Readers outside Florida need confirmation of both clinical availability and pharmacy shipment to their state before treating the offer as accessible.

FDA has received reports of errors measuring or administering compounded medication, some associated with hospitalization. That context supports asking the prescriber or pharmacist for clear product-specific instructions; it does not establish a Bailey-specific error rate. FDA also explicitly advises not using an injectable GLP-1 product that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. Our guide to cold-chain and delivery claims explains why shipping assurances need operational detail.

07Contact access is clearer than after-hours clinical coverage

The clinic publishes a St. Augustine address at 224 Southpark Circle East, Florida 32086, and telephone number (904) 342-4941. Listed office hours are Monday through Friday, 9 a.m.–noon and 2–6 p.m. Its contact form asks for a name, email address, phone number and service of interest. These provide practical ways to request details before enrollment, although the consulted documentation does not confirm a patient portal, interpretation services or Spanish-language care.

The GLP-1 page invites patients to call or text at any time and says the office will be responsive. That establishes an advertised contact channel, not round-the-clock clinical staffing or a guaranteed response interval. Before enrollment, patients can ask where medication concerns go after office hours and who reviews them. The distinction is especially important when the service includes home injections and the pharmacy’s identity is not publicly stated.

Bailey’s terms say SMS consent is not required to receive services. Replying STOP ends those messages unless the person opts in again; it is not a documented method of canceling treatment or billing. The privacy notice says mobile numbers and SMS opt-in data are not sold, rented or shared for third-party promotional purposes. That limited statement should not be expanded into a claim that the website does no tracking: the notice also discloses cookies and similar technologies.

08Document inconsistencies worth resolving before enrollment

Two inconsistencies deserve clarification without assuming misconduct. The homepage says “All Ages Welcome,” while terms effective October 1, 2023, say services, the website and communications are not intended for people under 18. The general homepage language therefore cannot establish that minors may join the GLP-1 program. Even for an adult-focused review, the mismatch matters because it shows that broad clinic messaging and formal terms do not always describe access consistently.

The contact form’s marketing-text consent names Bailey Spine & Wellness LLC, while the website and terms use Bailey Health Solutions. The consulted documentation does not explain the relationship between those names. A prospective patient can reasonably ask which entity provides care, bills the account and appears on consent documents. The discrepancy alone does not establish an improper arrangement; it leaves an identity question that clearer documentation could resolve.

The privacy notice recognizes access to an electronic health record, directing that record to a third party and requesting reasonable privacy-preserving communication arrangements. Those are useful published provisions. Its mixed references to different years make parts of the notice harder to interpret, without independently proving noncompliance. The terms also state that website content is informational and does not establish a provider-patient relationship—another reason to distinguish browsing the offer from receiving an actual clinical assessment.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Wilding et al. (2021): STEP 1 semaglutide trial ↗
4. Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
5. Bailey Health Solutions — official website ↗
6. Bailey Health Solutions — contact ↗
7. Bailey Health Solutions — glp1weightloss ↗
8. Bailey Health Solutions — terms and conditions ↗
9. Bailey Health Solutions — meet the team ↗
10. Bailey Health Solutions — notice of privacy practices ↗

Continue reading

• Same Ingredient Name, Different Evidence Questions
• A Clinical Trial Is Not a Telehealth Company Performance Report
• Follow-up Is a Clinical Question, Not Just a Renewal Notice
• Reading GLP-1 Cold-Chain and Delivery Claims Carefully